REG-Bioventix Plc: Notice of AGM <Origin Href="QuoteRef">BVXP.L</Origin>

BioventixAnnouncement

14/11/2016 11:50

Bioventix plc

(“Bioventix” or the “Company”)

Notice of AGM and Posting of Annual Report

Bioventix plc (AIM: BVXP) announces that its Annual General Meeting will be
held at The Winchester Suite, Farnham Castle, Farnham, Surrey, GU9 0AG at 2.00
p.m. on Wednesday 7 December 2016.

Copies of the 2016 Annual Report and the Notice of the Annual General Meeting
have been sent to shareholders and are also available on the Company's website
at www.bioventix.com.

For further information please contact:

 Bioventix plc Peter Harrison                       Chief Executive Officer              Tel: 01252 728 001  
                                                                                                             
 finnCap Ltd Geoff Nash/Simon Hicks Steve Norcross  Corporate Finance Corporate Broking  Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



Copyright (c) 2016 PR Newswire Association,LLC. All Rights Reserved